These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 21520037)

  • 21. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
    Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S; Drake AW; Tsuji I; Fan J
    PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
    Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
    Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway.
    Meira DD; Nóbrega I; de Almeida VH; Mororó JS; Cardoso AM; Silva RLA; Albano RM; Ferreira CG
    Eur J Cancer; 2009 May; 45(7):1265-1273. PubMed ID: 19167213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.
    Yoshida T; Okamoto I; Iwasa T; Fukuoka M; Nakagawa K
    FEBS Lett; 2008 Dec; 582(30):4125-30. PubMed ID: 19027738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A molecular view of anti-ErbB monoclonal antibody therapy.
    Leahy DJ
    Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
    Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
    Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multivalent Rhamnose-Modified EGFR-Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies.
    Li Y; Lin H; Hong H; Li D; Gong L; Zhao J; Wang Z; Wu Z
    Adv Sci (Weinh); 2024 Apr; 11(13):e2307613. PubMed ID: 38286668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.
    Boreddy SR; Nair R; Pandey PK; Kuriakose A; Marigowda SB; Dey C; Banerjee A; Kulkarni H; Sagar M; Krishn SR; Rao S; Ar M; Tiwari V; Alke B; Mv PK; Shri M; Dhamne C; Patel S; Sharma P; Periyasamy S; Bhatnagar J; Kuriakose MA; Reddy RB; Suresh A; Sreenivas S; Govindappa N; Moole PR; Bughani U; Tan SL; Nair P
    Cancer Res; 2023 Jun; 83(11):1883-1904. PubMed ID: 37074042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
    Quesnelle KM; Grandis JR
    Clin Cancer Res; 2011 Sep; 17(18):5935-44. PubMed ID: 21791633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
    Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
    Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
    Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
    J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expeditious Generation of Biparatopic Common Light Chain Antibodies
    Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2020; 11():606878. PubMed ID: 33424853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
    Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
    Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.